Related Experiment Video
Updated: Sep 10, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Capilliposide A attenuates diabetic nephropathy via modulation of NF-κB/TLR4 and apoptotic pathways
Xueli Man1,2, Luping Wang1,2, Huajun Liao3
1Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, Zhejiang, China.
Abstract:
This study aimed to identify therapeutic targets and signaling pathways of Capilliposide A (LC-A) for diabetic nephropathy (DN) through integrated network pharmacology and experimental validation. Using a DN mouse model induced by high-fat diet (HFD) and streptozotocin (STZ), we investigated the molecular mechanisms of LC-A. The PubChem database provided the two-dimensional structure of LC-A, with subsequent identification of LC-A/DN-associated targets through intersection analysis. Core targets were determined via protein-protein interaction (PPI) network construction, followed by gene ontology enrichment and pathway analyses. Molecular docking simulations evaluated LC-A's binding affinity to DN-related targets. C57BL/6 mice receiving HFD and STZ intraperitoneal injections were treated daily with LC-A or metformin (MET) via oral gavage for 8 weeks. Weekly monitoring included body weight and blood glucose measurements. Post-treatment assessments encompassed serum lipid profiles, renal function biomarkers, inflammatory cytokines, oxidative stress markers, and renal histopathology. Western blotting, immunohistochemistry, and immunofluorescence were performed to analyze inflammatory pathway proteins and apoptosis-related factors. Network pharmacology identified TLR4, NF-κB1, STAT3, EGFR, mTOR, and MAPK as core targets involved in inflammation, oxidative stress, and apoptosis regulation. Pathway enrichment analysis revealed critical inflammatory pathways including IL-17, TNF, and Th17 cell differentiation. Molecular docking confirmed stable binding of LC-A to TLR4, NF-κB1, Bax, and Bcl-2. In vivo experiments demonstrated that LC-A significantly reduced renal injury markers (KI, SCR, BUN), lipid profiles (TG, TC), and oxidative stress (MDA), while enhancing antioxidant enzymes (SOD, GPX, CAT) in DN mice (P < 0.05). LC-A effectively suppressed serum inflammatory cytokines (IL-6, TNF-α, IL-1β, MCP-1, iNOS) through NF-κB pathway modulation and apoptosis regulation (P < 0.05). Histopathological analysis revealed attenuated renal cortical vacuolization, tubular swelling, glomerular mesangial expansion, sclerosis, and inflammatory infiltration. These findings suggest LC-A as a promising natural nephroprotective agent for DN prevention and treatment.
Insights
Capilliposide A (LC-A) shows promise in treating diabetic nephropathy (DN) by targeting key inflammatory and oxidative stress pathways. This natural compound effectively reduced kidney damage markers and improved renal function in a mouse model.
Area of Science:
- Pharmacology
- Nephrology
- Molecular Biology
Background:
- Diabetic nephropathy (DN) is a major complication of diabetes, leading to significant kidney damage.
- Identifying novel therapeutic targets and pathways is crucial for effective DN treatment.
Purpose of the Study:
- To investigate the therapeutic targets and molecular mechanisms of Capilliposide A (LC-A) in diabetic nephropathy (DN).
- To validate the efficacy of LC-A using an integrated network pharmacology and experimental approach.
Main Methods:
- Network pharmacology identified core targets (TLR4, NF-κB1, STAT3, EGFR, mTOR, MAPK) and pathways (IL-17, TNF, Th17 cell differentiation).
- Molecular docking confirmed LC-A binding to TLR4, NF-κB1, Bax, and Bcl-2.
- A diabetic nephropathy mouse model was used for in vivo validation, assessing biochemical markers, inflammatory cytokines, oxidative stress, and renal histopathology.
Main Results:
- LC-A significantly reduced renal injury markers, lipid profiles, and oxidative stress in DN mice.
- LC-A suppressed inflammatory cytokines by modulating the NF-κB pathway and regulating apoptosis.
- Histopathological analysis showed attenuated renal damage, including reduced inflammation and glomerular mesangial expansion.
Conclusions:
- Capilliposide A (LC-A) demonstrates significant nephroprotective effects against diabetic nephropathy (DN).
- LC-A acts by modulating inflammation, oxidative stress, and apoptosis pathways.
- LC-A is a potential natural therapeutic agent for the prevention and treatment of DN.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
09:15Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model
Published on: October 10, 2017
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Dipeptidyl Peptidase 4 Inhibitors
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway